Menon Nithya, Perez-Velez Carlos M, Wheeler Jennifer A, Morris Michael F, Amabile Orazio L, Tasset Mark R, Raschke Robert A
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Banner - University Medical Center Phoenix - Arizona, United States.
Division of Infectious Diseases, Department of Medicine, Banner - University Medical Center Phoenix - Arizona, United States.
Rev Bras Ter Intensiva. 2017 Jul-Sep;29(3):271-278. doi: 10.5935/0103-507X.20170048. Epub 2017 Sep 28.
This report aimed to describe the outcomes of the patients with severe H1N1 associated acute respiratory distress syndrome who were treated with extracorporeal membrane oxygenation therapy.
This retrospective review analyzed a single-center cohort of adult patients with H1N1-related acute respiratory distress syndrome who were managed with veno-venous extracorporeal membrane oxygenation during the winter of 2013/2014.
A total of 10 patients received veno-venous extracorporeal membrane oxygenation for H1N1 influenza between January 2013 and March 2014. Seven patients were transferred to our center for extracorporeal membrane oxygenation consideration (all within 72 hours of initiating mechanical ventilation). The median patient age was forty years, and 30% were female. The median arterial oxygen partial pressure to fraction of inspired oxygen ratio was 62.5, and the median RESP score was 6. Three patients received inhaled nitric oxide, and four patients were proned as rescue therapy before extracorporeal membrane oxygenation was initiated. The median duration of mechanical ventilation was twenty-two days (range, 14 - 32). The median length of stay in the intensive care unit was twenty-seven days (range, 14 - 39). The median hospital length of stay was 29.1 days (range, 16.0 - 46.9). Minor bleeding complications occurred in 6 of 10 patients. Eight of the ten patients survived to hospital discharge.
The survivors were relatively young and discharged with good functional status (i.e., enhancing quality-adjusted life-years-saved). Our experience shows that even a relatively new extracorporeal membrane oxygenation program can play an important role in that capacity and provide excellent outcomes for the sickest patients.
本报告旨在描述接受体外膜肺氧合治疗的重症甲型H1N1流感相关急性呼吸窘迫综合征患者的治疗结果。
本回顾性研究分析了2013/2014年冬季在单中心接受静脉-静脉体外膜肺氧合治疗的甲型H1N1流感相关急性呼吸窘迫综合征成年患者队列。
2013年1月至2014年3月期间,共有10例患者因甲型H1N1流感接受静脉-静脉体外膜肺氧合治疗。7例患者因考虑进行体外膜肺氧合治疗而转至本中心(均在开始机械通气后72小时内)。患者中位年龄为40岁,30%为女性。动脉血氧分压与吸入氧分数比值的中位数为62.5,RESP评分的中位数为6。3例患者接受了吸入一氧化氮治疗,4例患者在开始体外膜肺氧合治疗前采用俯卧位作为挽救治疗。机械通气的中位持续时间为22天(范围14 - 32天)。重症监护病房的中位住院时间为27天(范围14 - 39天)。住院中位时间为29.1天(范围16.0 - 46.9天)。10例患者中有6例发生轻微出血并发症。10例患者中有8例存活至出院。
幸存者相对年轻,出院时功能状态良好(即增加了质量调整生命年)。我们的经验表明,即使是一个相对较新的体外膜肺氧合方案也能在这方面发挥重要作用,并为病情最严重的患者提供良好的治疗结果。